CLAIMS

1. The monohydrated sodium salt of S-tenatoprazole represented by the general formula (II) here-after:



2. A concentrated solution of monohydrated sodium salt of S-tenatoprazole, wherein the concentration in monohydrated salt is higher than or equal to 50 g/l.

3. A concentrated solution according to claim 2, wherein the concentration in monohydrated salt is higher than or equal to 100 g/l.

4. A pharmaceutical composition comprising the monohydrated sodium salt of S-tenatoprazole according to claim 1, associated to one or more pharmaceutically acceptable excipients and substrates.

5. A composition according to claim 4, wherein it is under the form of unitary doses containing from 10 to 80 mg of active principle.

6. A composition according to claim 5, wherein the unitary dose is comprised between 15 and 40 mg.

7. The use of the monohydrated sodium salt of S-tenatoprazole substantially free from the (+) enantiomer or R-tenatoprazole, for the treatment of digestive diseases.

8. The use of the monohydrated sodium salt of S-tenatoprazole for the manufacture of a medicinal product to treat digestive diseases where the inhibition of acid secretion must be effective and prolonged.

9. The use of the monohydrated sodium salt of S-tenatoprazole for the manufacture of a medicinal product to treat digestive diseases, gastro-oesophageal reflux disease and digestive bleeding in polymedicamented patients.

10. The use of the monohydrated sodium salt of S-tenatoprazole for the manufacture of a medicinal product exhibiting improved pharmacokinetic properties.

11. A method of preparation of the monohydrated sodium salt of S-tenatoprazole, wherein sodium hydroxide is caused to react on S-tenatoprazole at a temperature comprised between 50 and 70°C, and the salt obtained is precipitated after elimination of the solvent.

12. A method according to claim 11, wherein the reaction temperature is of about 60°C.

13. A method according to any of claim 11 and 12, wherein the reaction is conducted in a solvent such as water, chloroform, DMSO or a protic solvent, for example methanol or ethanol.

14. An enantioselective method of preparation of the monohydrated sodium salt of S-tenatoprazole, wherein an enantioselective oxidation is conducted on a sulphide of the following general formulation (I)



(I)

where A is a 4-methoxy-3,5-dimethyl-2-pyridyl group and B represents a 5-methoxy-imidazo[4,5-b]pyridyl group,
using an oxidising agent in the presence of a vanadium based catalyst and a chiral ligand in a specific sulphide solvent and a specific ligand solvent, followed by salification by sodium hydroxide, in order to obtain the monohydrated sodium salt of S-tenatoprazole.

15. A composition for oral administration of the monohydrated sodium salt of S-tenatoprazole, wherein it consists of a mixture of a diluent, a disintegrating agent and

the monohydrated sodium salt of S-tenatoprazole, this nucleus being covered with an enteric film.

16. A composition according to claim 15, wherein the diluent is a cellulosic diluent.

17. A composition according to claim 16, wherein the diluent is an excipient for direct compression.

18. A composition according to claim 15, wherein the disintegrating agent is a cellulosic polymer, such as a cellulose carboxymethyl polymer.

19. A composition according to claim 18, wherein the disintegrating agent is sodium croscarmellose.